CD59 (protectin) and CD46 (membrane cofactor protein, MCP) are membrane-bound complement regulator proteins which inhibit complement-mediated cytolysis of autologous cells. CD59, a phosphatidyl-inositol-anchored glycoprotein, inhibits the formation of the terminal membrane attack complex (MAC) of complement and was found to be a second ligand for CD2 contributing to T-cell activation. In 20 colorectal normal mucosa samples, in ten adenomas, 71 carcinomas and in ten liver metastases derived thereof, CD59 was inconsistently expressed in the epithelial compartment. In carcinomas CD59 expression in the whole neoplastic compartment was more often found in well-and moderately differentiated tumours. By contrast, focal expression or even complete lack of CD59 was more often found in poorly differentiated tumours (P = 0.021). In addition, carcinomas without metastases at the time of operation (Dukes A/B) more often expressed CD59 in the entire neoplastic population compared to those carcinomas which had already metastasised (P = 0.018). There was no correlation between the mode of CD59 expression in colorectal carcinomas and the tumour type or location. CD46 has C3b/C4b binding and factor-I dependent cofactor activity and is broadly expressed in various cells and tissues. In the epithelial compartment of normal colorectal mucosa, of all adenomas, carcinomas and their liver metastases, CD46 was expressed throughout the epithelial compartment.
Membrane-bound regulatory proteins protect autologous cells from complement mediated cytotoxicity when fragments of the complement cascade are deposited on host cells which are not the desired target (Davitz, 1986) . These proteins regulate the coordinating points in the classic and alternative pathways, the formation of the C3 convertases and the assembly of the terminal membrane attack complex (MAC) (Kinoshita, 1991) . One of these proteins which aids in regulating the latter is protectin or CD59 (Hadam, 1989a) , an 18-20 kD phosphatidyl-inositol anchored glycoprotein (Meri et al., 1990; Ratnoff et al., 1992) . CD59 restricts homologous lysis by binding to the C8 and C9 molecules during the MAC formation, thus disturbing the C8: C9 ratio in the MAC complex (Meri et al., 1990; Lachmann, 1991) . CD59 is broadly expressed in human tissues, in human blood cells and neoplastic haematopoietic cell lines (Davies et al., 1989) , vascular endothelia (Brooismans et al., 1992) , various ductal epithelia, in kidney, lung, skin and placenta (Lachmann, 1991; Meri et al., 1991; Rooney et al., 1991) , in thyroid follicular cells (Tandon et al., 1992) , and spermatozoa (Rooney et al., 1992) . However, CD59 might be involved in other immune regulatory mechanisms, such as signal transduction in cells (Stefanova et al., 1991) and T-cell activation and adhesion (Deckert et al., 1992; Venneker & Asghar, 1992) where it functions as a second ligand for CD2 (Hahn et al., 1992) . One protein which helps regulate the formation of the C3 convertases on autologous cells (Kinoshita, 1991) and the C5 convertase of the alternative complement pathway (Seya et al., 1991) is the 45-70 kD membrane cofactor protein (MCP) (Lublin & Atkinson, 1989) or CD46 (Hadam, 1989b) . This is a glycoprotein which acts on C3b and C4b and, as a cofactor, induces their factor I-mediated degradation (Seya et al., 1986; Liszewsky et al., 1991) . MCP is also broadly expressed, in human fibroblasts, epithelial, and endothelial cells (McNearney et al., 1989) , on human oocytes and the preimplantation blastocyst (Roberts et al., 1992) , on peripheral blood cells (Seya et al., 1990a; Cho et al., 1991) , in neoplastic haematopoietic cell lines (Caudwell et al., 1990; Seya et al., 1990a; Cho et al., 1991) (Dukes & Bussey, 1958) according to Turnbull et al. (Remmele, 1983) (Hadam, 1989a,b (Figure 1 ).
3/20 mucosae expressed CD59 only in about half of the epithelial compartments; 10 samples entirely lacked CD59 (Table I) . Despite this heterogeneous expression of CD59 in the epithelium, CD59 was broadly expressed in the sessile and mobile cells of the gut wall. The endothelial cells of small and large blood vessels strongly expressed CD59, as did the nerve fibre bundles of the autonomic plexus. Furthermore, fibrillar structures and fibroblasts in the interstitium were CD59 positive. The smooth muscle of the gut wall and in the arterial vessels expressed CD59 barely at all. Mononuclear cells of the mucosa and lymphoid cells in lymph follicles and in outer layers of the gut wall strongly expressed CD59.
Seven out of ten colorectal adenomas showed CD59 expression which was concentrated on the apical cell surface of the adenoma cells (Figure 2) . One adenoma lacked CD59 in about half of the epithelial cells and two others lacked CD59 entirely (Table I) .
In colorectal carcinomas CD59 expression was also heterogeneous. 42/71 cases showed CD59 antigen in all tumour cells, concentrated again on the apical cell border. 7/71 had more positive than negative neoplastic cells, 6/71 showed CD59 positive and negative tumour cells in about equal parts; 5/71 tumours were predominantly negative and 11/71 entirely lacked CD59 in their epithelial compartment (Figure 3 ). Stromal cells showed the same staining pattern as the normal gut wall. In addition, fibrillar structures and fibroblasts of the tumour stroma strongly expressed CD59. From 41 carcinomas of the Dukes A and B group, 29 expressed CD59 in the whole tumour and 12 showed a focal expression or a complete loss of CD59. In contrast, from 30 carcinomas of the Dukes C and D group, only 13 carcinomas expressed CD59 in the whole tumour compartment, whereas 17 carcinomas showed a focal expression or a complete loss. Tumours expressing CD59 in the whole epithelium were found more often in the Dukes A/B group than in Dukes C/D (P = 0.018), i.e. CD59 was more often expressed in tumours without lymph node or liver metastases than in tumours that had metastasised at the time of operation. From 52 grade I and II carcinomas 35 expressed CD59 in the whole tumour and 17 showed a focal expression or a complete loss. In contrast, from 19 grade III carcinomas only seven expressed CD59 in the whole tumour and 12 showed a focal expression or a complete loss. Well-and moderately differentiated tumours more often expressed CD59 in the whole epithelial compartment compared to less differentiated tumours (P = 0.021).
There was no significant correlation between the mode of CD59 expression and the tumour type or location.
In the ten liver metastases CD59 expression mainly corresponded to that found in their primaries. In 6/10 metastases a similar expression of CD59 was found when compared with their primary tumours, in 1/10 a lower antigen expression was found, and in 3/10 a higher expression of CD59 was found in the metastases. Peritumorous hepatocytes of the liver metastases were CD59-negtive. The bile ducts and bile ductuli were strongly CD59-positive, as were the sinusoids and the endothelial cells of larger blood vessels (Figure 4 ).
CD46
In normal colorectal mucosa CD46 was expressed throughout the epithelium with no microtopographic differences along the crypts. Although the cell membranes were prominently stained, the cytoplasmic compartment was strongly positive, too ( Figure 5 ). CD46 was also broadly expressed in the sessile and mobile cells of the gut wall: CD46 antigen density was high in endothelial cells of small and large blood vessels, intermediate in smooth muscle cells of the gut wall and the blood vessels, as well as in the nerve fibre bundles of the gut plexus, and low in a subset of fibroblasts and fibrillar structures. Most of the mononuclear cells within the lamina propria were CD46-positive. Lymphocytic cells and dendritic cells of lymph follicles strongly expressed CD46. In colorectal adenomas CD46 was found in the epithelium of all ten tumours with a staining pattern and antigen intensity corresponding to the CD46 expression in normal mucosa ( Figure 6 ).
CD46 was consistently expressed in all colorectal carcinomas ( Figure 7 , Table I ). The CD46 antigen density was often found to be higher in the neoplastic than in the adjacent non-neoplastic epithelium. The tumour stroma, i.e. fibroblasts and fibrillar structures, were slightly CD46-positive.
The cells of the liver metastases examined were likewise strongly CD46-positive (Figure 8 ). CD46 expression was at a high level in the biliary ductuli and ducts and in the sinusoidal system of the surrounding liver parenchyma, the hepatocytes were slightly CD46-positive.
Immunocytochemistry and FACScan®' analysis Cytospin preparations from SW480 and HT29 showed a strong expression of CD59 ( Figure 9 ) and CD46 ( Figure 10 ) in the cytoplasm. The maximum antigen density, however, was confined to the cell membrane. The FACScan® analysis demonstrated that under cell culture conditions both complement regulatory proteins were strongly surface-expressed on both colon carcinoma lines (Figure 11 ).
Discussion
Recently, we have reported that the decay-accelerating factor (DAF, CD55) is only sporadically expressed in colorectal epithelium, but is up-regulated in considerable percentages of colon adenomas and carcinomas. Expression was especially high in carcinomas of the mucinous type (Koretz et al., 1992) , which itself has a poorer prognosis than non-mucinous colorectal carcinomas. The present study adds further insight in the expression of complement regulatory membrane proteins in normal and neoplastic colorectal epithelium. CD59 expression was found to be heterogeneous in both normal and neoplastic conditions. In normal colorectal epithelium, presence vs absence of CD59 was not associated with any obvious microtopographical condition. In colorectal carcinomas the expression of CD59 was correlated with their grade of differentiation and the stage of the disease, i.e., carcinomas exhibiting a low grade of differentiation and carcinomas which had already metastasized at the time of operation significantly more often lacked CD59 in the neoplastic compartment. The biological effects of complement regulatory proteins CD55 and CD59 on colon epithelium are unknown. It has been suggested that presence of CD55 and presence or upregulation of CD59 are crucial in preventing a potential cell lysis by autologous complement (Davitz, 1986; Tandon et al., 1992) . We have shown here that CD46 is consistently expressed in normal and neoplastic colorectal epithelium. Thus, the physiological regulation of CD46 expression is unaffected by neoplastic transformation in this cell type. Since CD46 alone sufficiently inhibits the complement cascade at an early stage in some cell lines (Seya et al., 1990b) , the appearance of complement-inhibitors that act during later steps might be redundant. As the biological functions of cell-surface complement regulator proteins on colon epithelium are unknown at present, their possible involvement in tumour surveillance will have to be investigated in in vitro studies.
Apart from their complement regulatory role, CD55 and CD59 have recently been shown to exhibit additional immune functions. CD55 expression on target cells had an inhibitory effect on cytotoxicity by natural killer cells (Finberg et al., 1992) . CD59 was demonstrated to adhere to and activate T-cells (Deckert et al., 1992) through its capacity to interact with CD2 (Hahn et al., 1992) . The binding site on CD2 for CD59 was found overlapping but nonidentical with the binding site of the well-known counter receptor which is the lymphocyte function-associated antigen-3 (LFA-3; CD58) (Hahn et al., 1992) . In vitro, both CD58 and CD59 antibody alone were shown to reduce the CD2-dependent response of a murine T-cell clone expressing human CD2 (Hahn et al., 1992) . It is thus conceivable that presence of CD59 on the cell surface might compensate a reduction or loss of LFA-3 (CD58) which has been reported to occur in some colorectal carcinomas (Smith et al., 1989; Koretz et al., 1991) . In view of the novel functions attributed to CD55 and CD59, presence of CD55 and absence of CD59 might contribute to resistance of a tumour cell to cell-mediated cytotoxicity unrestricted and restricted, respectively, by the major histocompatibility complex (Browning & Bodmer, 1992; Moller & Hammerling, 1992) .
CD59 and CD46 are cell surface molecules known to act as complement regulator proteins. The functional properties of CD59 suggest it belongs to the group of cell surface molecules that are involved in T-cell -target-cell interaction and CD59 might therefore play a role in MHC-restricted cytotoxicity. The role of CD59 in colorectal carcinoma remains to be elucidated in functional studies.
